Mariël L te Winkel1, Rob Pieters2, Wim C J Hop3, Jan C Roos4, Jos P M Bökkerink5, Jan A Leeuw6, Marrie C A Bruin7, Wouter J W Kollen8, Anjo J P Veerman9, Hester A de Groot-Kruseman10, Inge M van der Sluis1, Marry M van den Heuvel-Eibrink11. 1. Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands. 2. Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands; Dutch Childhood Oncology Group, The Hague, The Netherlands. 3. Department of Biostatistics, Erasmus MC - University Medical Center, Rotterdam, The Netherlands. 4. Department of Radiology, VU University Medical Center, Amsterdam, The Netherlands. 5. Dutch Childhood Oncology Group, The Hague, The Netherlands; Department of Pediatric Oncology/Hematology, University Medical Center St Radboud, Nijmegen, The Netherlands. 6. Dutch Childhood Oncology Group, The Hague, The Netherlands; Department of Pediatric Oncology, Beatrix Children's Hospital, University of Groningen, Groningen, The Netherlands. 7. Dutch Childhood Oncology Group, The Hague, The Netherlands; Department of Pediatric Oncology, University Medical Center Utrecht, Utrecht, The Netherlands. 8. Dutch Childhood Oncology Group, The Hague, The Netherlands; Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands. 9. Dutch Childhood Oncology Group, The Hague, The Netherlands; Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands. 10. Dutch Childhood Oncology Group, The Hague, The Netherlands. 11. Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands; Dutch Childhood Oncology Group, The Hague, The Netherlands. Electronic address: m.vandenheuvel@erasmusmc.nl.
Abstract
PURPOSE: To elucidate incidence and risk factors of bone mineral density and fracture risk in children with Acute Lymphoblastic Leukemia (ALL). METHODS: Prospectively, cumulative fracture incidence, calculated from diagnosis until one year after cessation of treatment, was assessed in 672 patients. This fracture incidence was compared between subgroups of treatment stratification and age subgroups (Log-Rank test). Serial measurements of bone mineral density of the lumbar spine (BMDLS) were performed in 399 ALL patients using dual energy X-ray absorptiometry. We evaluated risk factors for a low BMD (multivariate regression analysis). Osteoporosis was defined as a BMDLS≤-2 SDS combined with clinical significant fractures. RESULTS: The 3-year cumulative fracture incidence was 17.8%. At diagnosis, mean BMDLS of ALL patients was lower than of healthy peers (mean BMDLS=-1.10 SDS, P<0.001), and remained lower during/after treatment (8months: BMDLS=-1.10 SDS, P<0.001; 24months: BMDLS=-1.27 SDS, P<0.001; 36months: BMDLS=-0.95 SDS, P<0.001). Younger age, lower weight and B-cell-immunophenotype were associated with a lower BMDLS at diagnosis. After correction for weight, height, gender and immunophenotype, stratification to the high risk (HR)-protocol arm and older age lead to a larger decline of BMDLS (HR group: β=-0.52, P<0.01; age: β=-0.16, P<0.001). Cumulative fracture incidences were not different between ALL risk groups and age groups. Patients with fractures had a lower BMDLS during treatment than those without fractures. Treatment-related bone loss was similar in patients with and without fractures (respectively: ΔBMDLS=-0.36 SDS and ΔBMDLS=-0.12 SDS; interaction group time, P=0.30). Twenty of the 399 patients (5%) met the criteria of osteoporosis. CONCLUSION: Low values of BMDLS at diagnosis and during treatment, rather than the treatment-related decline of BMDLS, determine the increased fracture risk of 17.8% in children with ALL.
PURPOSE: To elucidate incidence and risk factors of bone mineral density and fracture risk in children with Acute Lymphoblastic Leukemia (ALL). METHODS: Prospectively, cumulative fracture incidence, calculated from diagnosis until one year after cessation of treatment, was assessed in 672 patients. This fracture incidence was compared between subgroups of treatment stratification and age subgroups (Log-Rank test). Serial measurements of bone mineral density of the lumbar spine (BMDLS) were performed in 399 ALL patients using dual energy X-ray absorptiometry. We evaluated risk factors for a low BMD (multivariate regression analysis). Osteoporosis was defined as a BMDLS≤-2 SDS combined with clinical significant fractures. RESULTS: The 3-year cumulative fracture incidence was 17.8%. At diagnosis, mean BMDLS of ALL patients was lower than of healthy peers (mean BMDLS=-1.10 SDS, P<0.001), and remained lower during/after treatment (8months: BMDLS=-1.10 SDS, P<0.001; 24months: BMDLS=-1.27 SDS, P<0.001; 36months: BMDLS=-0.95 SDS, P<0.001). Younger age, lower weight and B-cell-immunophenotype were associated with a lower BMDLS at diagnosis. After correction for weight, height, gender and immunophenotype, stratification to the high risk (HR)-protocol arm and older age lead to a larger decline of BMDLS (HR group: β=-0.52, P<0.01; age: β=-0.16, P<0.001). Cumulative fracture incidences were not different between ALL risk groups and age groups. Patients with fractures had a lower BMDLS during treatment than those without fractures. Treatment-related bone loss was similar in patients with and without fractures (respectively: ΔBMDLS=-0.36 SDS and ΔBMDLS=-0.12 SDS; interaction group time, P=0.30). Twenty of the 399 patients (5%) met the criteria of osteoporosis. CONCLUSION: Low values of BMDLS at diagnosis and during treatment, rather than the treatment-related decline of BMDLS, determine the increased fracture risk of 17.8% in children with ALL.
Authors: Elizabeth A Cummings; Jinhui Ma; Conrad V Fernandez; Jacqueline Halton; Nathalie Alos; Paivi M Miettunen; Jacob L Jaremko; Josephine Ho; Nazih Shenouda; Mary Ann Matzinger; Brian Lentle; David Stephure; Robert Stein; Ann Marie Sbrocchi; Celia Rodd; Bianca Lang; Sara Israels; Ronald M Grant; Robert Couch; Ronald Barr; John Hay; Frank Rauch; Kerry Siminoski; Leanne M Ward Journal: J Clin Endocrinol Metab Date: 2015-07-14 Impact factor: 5.958
Authors: Hiroto Inaba; Xueyuan Cao; Alice Q Han; John C Panetta; Kirsten K Ness; Monika L Metzger; Jeffrey E Rubnitz; Raul C Ribeiro; John T Sandlund; Sima Jeha; Cheng Cheng; Ching-Hon Pui; Mary V Relling; Sue C Kaste Journal: Cancer Date: 2017-12-19 Impact factor: 6.860
Authors: Marissa A H den Hoed; Saskia M F Pluijm; Mariël L te Winkel; Hester A de Groot-Kruseman; Martha Fiocco; Peter Hoogerbrugge; Jan A Leeuw; Marrie C A Bruin; Inge M van der Sluis; Dorien Bresters; Maarten H Lequin; Jan C Roos; Anjo J P Veerman; Rob Pieters; Marry M van den Heuvel-Eibrink Journal: Haematologica Date: 2015-09-24 Impact factor: 9.941
Authors: M A H den Hoed; B C Klap; M L te Winkel; R Pieters; M van Waas; S J C M M Neggers; A M Boot; K Blijdorp; W van Dorp; S M F Pluijm; M M van den Heuvel-Eibrink Journal: Osteoporos Int Date: 2014-09-11 Impact factor: 4.507
Authors: Jenneke E van Atteveld; Saskia M F Pluijm; Kirsten K Ness; Melissa M Hudson; Wassim Chemaitilly; Sue C Kaste; Leslie L Robison; Sebastian J C M M Neggers; Yutaka Yasui; Marry M van den Heuvel-Eibrink; Carmen L Wilson Journal: J Clin Oncol Date: 2019-05-31 Impact factor: 50.717
Authors: Jenneke E van Atteveld; Iris E Verhagen; Marry M van den Heuvel-Eibrink; Hanneke M van Santen; Inge M van der Sluis; Natascia Di Iorgi; Jill H Simmons; Leanne M Ward; Sebastian J C M M Neggers Journal: Cancer Med Date: 2021-06-08 Impact factor: 4.452
Authors: Jenneke E van Atteveld; Demi Tc de Winter; Rob Pieters; Sebastian Jcmm Neggers; Marry M van den Heuvel-Eibrink Journal: Fac Rev Date: 2021-06-23